Regulus Therapeutics' Phase 1b study shows farabursen 300 mg slowed kidney volume growth in ADPKD patients with a favorable ...

Regulus Therapeutics (RGLS) stock soars after positive Phase 1b trial data for the company's lead asset, farabursen against a ...

Regulus Therapeutics Inc.’s RGLS share price has surged by 16.28%, which has investors questioning if this is right time to ...

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at ...

Wells Fargo & Company upgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) from an equal weight rating to an ...

Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.4% following an upgrade from Wells Fargo (NYSE: WFC) ...

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Regulus (RGLS – Research Report) today and set a price target of $7.00. The ...

Regulus Therapeutics (NASDAQ:RGLS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Canaccord Genuity Group in a research note issued on Monday,Benzinga reports. They ...

Fintel reports that on March 27, 2025, Wells Fargo upgraded their outlook for Regulus Therapeutics (NasdaqCM:RGLS) from Equal ...

In this article, we are going to take a look at where Regulus Therapeutics Inc. (NASDAQ:RGLS) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs ...

Fintel reports that on March 27, 2025, Wells Fargo upgraded their outlook for Regulus Therapeutics (NasdaqCM:RGLS) from Equal-Weight to Overweight. As of March 19, 2025, the average one-year price ...